Radius Health (RDUS) Stock Price
Radius Health Price
Over the last 19 years Radius Health grew revenue by 6.3% annually, reaching 2.74 B USD. Earnings per share have grown at 1.5% per year over the last 17 years. For Radius Health, the net margin of -9.7% is down versus -0.2% a few years ago. At today's price the dividend yield works out to roughly 2.50%. The dividend has grown at 13.5% per year over the past 19 years. The consensus 12-month price target for Radius Health is 18.36 USD, about 38.8% below where the stock trades today. Of 8 analysts, 0 rate the stock a buy — an overall Hold consensus.
Radius Health stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Radius Health over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Radius Health stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Radius Health's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Radius Health Price |
|---|
Radius Health Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Radius Health Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.54 | 1.92 | 1.35 | 0.02 | 0.10 | 0.17 | 1.71 | 2.76 | 3.49 | 2.88 | 2.74 | 2.85 | 2.96 | 3.23 | 2.85 | 2.90 |
| -2.98 | -24.70 | -29.40 | -98.37 | 350.00 | 74.75 | 889.60 | 61.10 | 26.36 | -17.30 | -5.00 | 2.37 | 3.76 | 9.17 | -11.59 | 1.58 |
| 8.57 | 8.98 | 13.02 | 90.91 | 90.91 | 90.75 | 12.15 | 16.42 | 14.00 | 10.65 | 6.46 | 6.46 | 6.46 | 6.46 | 6.46 | 6.46 |
| 218.00 | 172.00 | 176.00 | 20.00 | 90.00 | 157.00 | 208.00 | 453.00 | 488.00 | 307.00 | 177.00 | 184.18 | 191.09 | 208.61 | 184.43 | 187.34 |
| 20.00 | -99.00 | -184.00 | -246.00 | -198.00 | -108.00 | 6.00 | 213.00 | 225.00 | -3.00 | -294.00 | -59.00 | -28.00 | -30.00 | -26.00 | -27.00 |
| 0.79 | -5.17 | -13.61 | -1,118.18 | -200.00 | -62.43 | 0.35 | 7.72 | 6.46 | -0.10 | -10.74 | -2.07 | -0.95 | -0.93 | -0.91 | -0.93 |
| 5.00 | -101.00 | -182.00 | -254.00 | -221.00 | -132.00 | -4.00 | 165.00 | 168.00 | -25.00 | -266.00 | -79.00 | 7.00 | 35.00 | 67.00 | 78.00 |
| -108.33 | -2,120.00 | 80.20 | 39.56 | -12.99 | -40.27 | -96.97 | -4,225.00 | 1.82 | -114.88 | 964.00 | -70.30 | – | 400.00 | 91.43 | 16.42 |
| 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | – | – | – |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| 26.94 | 42.92 | 43.12 | 28.66 | 45.55 | 46.18 | 46.65 | 47.33 | 27.72 | 28.22 | 28.57 | 28.57 | 28.57 | 28.57 | 28.57 | 28.57 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Radius Health generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Radius Health retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Radius Health's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Radius Health has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Radius Health's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Radius Health stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Radius Health Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Radius Health business model & stock analysis
Radius Health SWOT Analysis
Strengths
- Strong market presence and recognition in the healthcare industry.
- Unique expertise in developing innovative treatments for osteoporosis.
- Solid financial position with steady revenue growth.
- Strong research and development capabilities.
- Well-established distribution network and partnerships with key stakeholders.
Weaknesses
- Lack of diversification in product portfolio, heavily reliant on osteoporosis treatments.
- Vulnerability to fluctuations in healthcare policies and regulations.
- Limited geographic reach, primarily focused on specific markets.
- Challenges in scaling up production and meeting increasing demand.
- Limited patents and potential intellectual property risks.
Opportunities
- Increasing global geriatric population presents a growing market for osteoporosis treatments.
- Expansion into new markets and diversification of product portfolio.
- Strategic collaborations and partnerships with pharmaceutical companies.
- Potential for advancements in research and development of new treatment options.
- Growing emphasis on preventative healthcare and wellness.
Threats
- Intense competition from established pharmaceutical companies.
- Potential for regulatory hurdles and delays in product approvals.
- Pricing pressures and reimbursement challenges.
- Technological advancements leading to the development of alternative treatments.
- Economic downturns impacting consumer spending on healthcare products.
Radius Health Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Radius Health Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Radius Health historical P/E ratio, EBIT multiple, and P/S ratio
Radius Health annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Radius Health shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Radius Health stock splits
Radius Health Dividend History
32 years of dividend payments
Radius Health dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Radius Health dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Radius Health forecasts and price targets in August 2026
Analyst Price Targets 2026Radius Health Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 5/30/2024 | Upgrade | SellNeutral | – | |
| 3/15/2024 | Maintained | Sell | – | |
| 2/28/2024 | Downgrade | BuySell | – | |
| 10/5/2022 | Maintained | Buy | – | |
| 6/24/2022 | Maintained | Market PerformPerform | – | |
| 6/8/2022 | Upgrade | UnderperformNeutral | 70 | |
| 5/30/2022 | Maintained | Buy | – | |
| 5/24/2022 | Maintained | Neutral | – | |
| 5/23/2022 | Maintained | Market PerformPerform | – | |
| 5/18/2022 | Downgrade | OverweightSector Weight | 49 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Radius Health Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 6/29/2026 | 0.21USD | - | 842.57 MUSD | - | 2026 Q3 |
| 4/2/2026 | -0.05USD | - | 754.44 MUSD | - | 2026 Q2 |
| 1/5/2026 | -0.01USD | - | 762.83 MUSD | - | 2026 Q1 |
| 6/25/2024 | 0.43USD | - | 747.76 MUSD | - | 2024 Q3 |
| 4/3/2024 | -0.21USD | - | 647.29 MUSD | - | 2024 Q2 |
| 5/3/2023 | -0.05USD | - | 52.48 MUSD | - | 2023 Q1 |
| 2/22/2023 | 0.18USD | - | 72.69 MUSD | - | 2022 Q4 |
| 11/29/2022 | -0.04USD | - | 61.88 MUSD | - | 2022 Q3 |
| 8/30/2022 | 0.03USD | - | 66.32 MUSD | - | 2022 Q2 |
| 5/5/2022 | -0.22USD | - | 52.06 MUSD | - | 2022 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Radius Health stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Radius Health shareholder structure
| % | Name |
|---|---|
30.95520% | |
24.48994% | |
8.15528% | |
6.23394% | |
6.23394% | |
0.71748% |
Radius Health Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
14.62% | SEC ↗ | |
14.62% | SEC ↗ | |
10.90% | SEC ↗ | |
8.68% | SEC ↗ | |
8.20% | SEC ↗ | |
8.20% | SEC ↗ | |
8.20% | SEC ↗ | |
8.20% | SEC ↗ | |
7.40% | SEC ↗ | |
7.10% | SEC ↗ |
Radius Health Executives and Management Board
13 members · avg. age 62 · 31 % women
Mr. G. Kelly Martin (62)
President, Chief Executive Officer, Director · since 2020
11.96 M USD
Management
Mr. Salvador Grausso (46)
Senior Vice President, Head of U.S. Patient Access
Mr. Mike Conley (60)
Chief Financial Officer, Vice President, Treasurer
Ms. Chhaya Shah (57)
Senior Vice President , Chief Business Officer
Ms. Kim Clarke
General Counsel
Mr. Ethan Holdaway
Investor Relations · since 2020
Board of Directors
Mr. Owen Hughes (46)
Independent Chairman of the Board
Ms. Catherine Friedman (61)
Independent Director
Dr. Jean-Pierre Garnier (74)
Independent Director
Dr. Willard Dere (67)
Independent Director
Mr. Sean Murphy (68)
Independent Director
Ms. Machelle Sanders (58)
Independent Director
Frequently asked questions about Radius Health
The business model of Radius Health Inc revolves around developing and commercializing innovative therapeutics to address unmet medical needs in the field of osteoporosis and other endocrine-related diseases. The company focuses on researching, developing, and marketing solutions that target the underlying causes of these conditions. By utilizing its expertise in hormone biology and technology platforms, Radius Health aims to provide patients with effective treatments that improve their overall health and quality of life. With a focus on delivering value and advancing scientific understanding, Radius Health Inc aims to be a leading player in the pharmaceutical industry.
Radius Health Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Radius Health Inc in the market include pharmaceutical companies such as Amgen Inc, Eli Lilly and Company, and Novartis AG.
Radius Health Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics in the field of osteoporosis and oncology. Founded in 2003, Radius Health Inc has established itself as a leader in the bone health market. The company's flagship product, TYMLOS®, is an FDA-approved therapy for postmenopausal women at high risk for fracture. With a strong team of experienced professionals and a robust pipeline of potential future treatments, Radius Health Inc continues to strive towards improving patient outcomes and addressing unmet medical needs in the areas of bone health and oncology.
Radius Health Inc has achieved significant milestones in its history. Some notable achievements include gaining FDA approval for their osteoporosis treatment drug, Tymlos, which has shown promising results in clinical trials. The company has also successfully expanded its market presence, solidifying partnerships with well-established pharmaceutical companies. Additionally, Radius Health Inc has made advancements in its research and development efforts, focusing on enhancing their product pipeline. These achievements demonstrate the company's commitment to providing innovative solutions for patients' healthcare needs.
Radius Health Inc is primarily present in the United States.
Radius Health Inc is a pharmaceutical company that is committed to improving the health and well-being of patients. With a strong corporate philosophy focused on innovation, research, and collaboration, Radius Health Inc strives to bring innovative and effective treatment options to the market. The company is dedicated to improving patient outcomes and providing value for both patients and shareholders. Through its dedication to research and development, Radius Health Inc aims to make a positive impact in the healthcare industry and contribute to the advancement of medical science.
Analysts currently set an average price target of 18.36 USD for the Radius Health stock (median: 18.36 USD), implying -38.8 % versus the latest price. The consensus is based on 8 analyst ratings.
7 analysts currently rate the Radius Health stock: 0 recommend buying, 4 holding and 3 selling. For 2026, analysts expect Radius Health to generate revenue of 2.96 B USD and earnings per share of 0.27 USD.
Converted at the current exchange rate, the Radius Health share trades at 25.99 EUR (30.00 USD).
The Radius Health share (RDUS) is listed on 4 stock exchanges, including: NASDAQ (RDUS), Frankfurt (1R8.F), Düsseldorf (1R8.DU), SIX (Zürich) (1R8.SW).
Radius Health Inc is a pharmaceutical company that specializes in researching, developing, and marketing medications for the prevention and treatment of osteoporosis. The company was founded in 2003 and is headquartered in Waltham, Massachusetts, USA. The business model of Radius Health includes three main divisions: research and development, sales and marketing, and partnerships and licensing. In the area of research and development, the company continuously works on developing new medications that meet the needs of patients with osteoporosis and other bone diseases. The latest scientific methods are used to deepen the understanding of these diseases and their causes. On the other hand, the sales and marketing department of Radius Health is responsible for bringing the already developed medications into the market. The company works closely with doctors, hospitals, and other healthcare facilities to ensure that the medications are used correctly by patients. In addition, public relations efforts are made to raise awareness of osteoporosis and other bone diseases and to emphasize the importance of preventive measures. The third division of Radius Health deals with partnerships and licensing. The company collaborates with other pharmaceutical companies and research institutions to create synergies and share research findings. The company also licenses its already developed medications to other companies for sale in specific markets. An important component of Radius Health's business model is the products it offers. The company's most well-known medication is TYMLOS, which contains the active ingredient Abaloparatide. By specifically targeting bone metabolism, TYMLOS can help reduce the risk of fractures in women with postmenopausal osteoporosis. Another product is the preparation BAQSIMI, which is used to treat severe hypoglycemic shock in diabetes patients. In summary, Radius Health's business model is focused on developing and bringing to market innovative and effective medications for the prevention and treatment of osteoporosis. Through targeted research and development, intensive sales and marketing efforts, and partnerships and licensing, the company aims to strengthen awareness of bone diseases, improve patients' quality of life, and become a leading company in the industry.
The expected revenue of Radius Health is 2.96 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Radius Health is 7.67 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Radius Health is currently 111.72. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Radius Health stock.
The price-to-sales ratio (P/S) of Radius Health is currently 0.29. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Radius Health stock.
The Eulerpool Quality Score for Radius Health is 1/10.
The ISIN of Radius Health is US7504692077. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Radius Health is A114VH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Radius Health is RDUS. The ticker symbol is used to trade Radius Health shares on the stock exchange.
Over the past 12 months, Radius Health paid a dividend of 0.75 USD . This corresponds to a dividend yield of about 2.50 %. For the coming 12 months, Radius Health is expected to pay a dividend of 0.75 USD.
The current dividend yield of Radius Health is 2.50 %.
Radius Health pays a dividend, distributed in the months of , , , .
Radius Health paid dividends every year for the past 32 years.
For the upcoming 12 months, dividends amounting to 0.75 USD are expected. This corresponds to a dividend yield of 2.50 %.
Radius Health is assigned to the 'Health' sector.
To receive the latest dividend of Radius Health from amounting to 0.19 USD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
In the year 2025, Radius Health distributed 0.56 USD as dividends.
The dividends of Radius Health are distributed in USD.
Radius Health stock
Radius Health Peer Group
Radius Health Ticker
Radius Health FIGI
All fundamentals and in-depth analysis of Radius Health
Our stock analysis for Radius Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Radius Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.